Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma

Received 24 April 2009; received in revised form 1 August 2009; accepted 11 August 2009. published online 07 September 2009.

Abstract

Twelve patients with locally advanced esophageal squamous cell carcinoma were enrolled to evaluate the safety and efficacy of concurrent chemo-radiotherapy. Dose-limiting toxicity was mainly observed at Capecitabine 1500mg. The maximum-tolerated dose/recommended dose of Capecitabine was 1000mg. The Kaplan–Meier estimated overall l-year survival rate was 100%.

Keywords: Esophageal cancer, Selective lymph node late course accelerated hyper-fractionated radiotherapy, Chemo-radiotherapy, Capecitabine, Cisplatin

a Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China

b Department of Medicine Oncology, Shandong Cancer Hospital, Shandong Province, PR China

Corresponding author. Address: Department of Medicine Oncology, Shandong Cancer Hospital, No. 440, Ji-Yan Rd., Ji-Nan, Shandong Province, PR China.

PII: S0167-8140(09)00435-6

doi:10.1016/j.radonc.2009.08.002

15 of 52